|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0652 - 0.0707|
|52 Week Range||0.0200 - 0.0920|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 31, 2017 - Apr 3, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.50|
KNOXVILLE, TN, July 10, 2018-- Provectus today announced that a clinical trials update was provided at the 8th European Post-Chicago Melanoma/Skin Cancer Meeting, held in Munich, Germany from June 28-29.. ...
KNOXVILLE, TN, June 19, 2018-- Provectus today announced that the Indian Patent Office has granted the Company’ s patent application for the synthetic process used to produce the active pharmaceutical ...
KNOXVILLE, TN & NEW YORK, NY, May 17, 2018 (GLOBE NEWSWIRE) -- Provectus and POETIC today announced preclinical PV-10 data from pediatric cancer research that will be presented at the 2018 American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, IL. Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”) is a clinical-stage biotechnology company developing PV-10 as the first small molecule oncolytic immunotherapy for adult and pediatric solid tumor cancers.
Data presentation planned for first half of 2019. KNOXVILLE, TN, May 07, 2018-- Provectus today announced the completion of enrollment of 24 patients with metastatic melanoma into the Phase 1 b portion ...
Combinations with PV-10 included+ anti-CTLA-4;+ anti-PD-1;+ anti-PD-L1; and,+ anti-PD-1+ Treg depletion Data provided basis for ongoing Phase 1 b/2 study of PV-10 in combination with KEYTRUDA ® for Stage ...
KNOXVILLE, TN & NEW YORK, NY, April 25, 2018 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a clinical-stage biotechnology company developing PV-10 as the first small molecule oncolytic immunotherapy for solid tumor cancers, and the Pediatric Oncology Experimental Therapeutics Investigators' Consortium (“POETIC”), a group of North American academic medical centers developing new pediatric cancer therapies, today announced that preclinical data from ongoing pediatric cancer research into PV-10 will be presented in a poster presentation at the American Society of Clinical Oncology (“ASCO”) Annual Meeting held in Chicago, IL from June 1-5, 2018.
Ed Pershing, CPA elected new Board chair Jack Lacey, MD named new Board director; also appointed new strategic advisory board chair. KNOXVILLE, TN, April 24, 2018-- Provectus Biopharmaceuticals, Inc., ...